News | September 28, 2021
Bal Pharma ramps up API capacity of Gliclazide
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
Barbara Engelhardt moves her computational and statistics lab to Gladstone
Packaged junk food which is a major component of unhealthy diets is responsible for more deaths worldwide than any other risk factor
New treatment options are critical, as approximately half of all people with heart failure die within five years of diagnosis. Heart failure accounts for more than one million hospitalisations a year in the US
FDA approval of the first interchangeable biosimilar insulin will drive the US Insulin biosimilar market, says Kuick Research.
It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
The company is eligible for 12 months exclusivity from launch
Sitagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
The TWYMEEG approval is supported by numerous preclinical and clinical studies, including the Phase 3 TIMES (Trials of IMeglimin for Efficacy and Safety) program managed jointly by both the companies
Promising drug pipeline, focus on gene therapy and innovative digital health solutions will remain the key pillars of Bayer’s pharmaceutical business
Subscribe To Our Newsletter & Stay Updated
